+17.2%
ABNB vs MRNA
-10.3%
+27.5%
-62.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.8% | -3.4% | +0.6% | -2.5% |
| 7D | -7.4% | -10.1% | +2.6% | -6.6% |
| 30D | -8.2% | +126.7% | -134.9% | -20.7% |
| 3M | +29.1% | +184.1% | -155.0% | +6.7% |
| 6M | +26.6% | +143.3% | -116.7% | +6.9% |
| YTD | +25.0% | +359.9% | -334.9% | -5.9% |
| 1Y | +37.0% | +454.2% | -417.2% | -1.0% |
| 3Y | +16.3% | +26.0% | -9.7% | +0.9% |
| 5Y | +2.2% | -70.3% | +72.4% | -4.3% |
| All | +17.2% | -10.3% | +27.5% | -12.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling